Sonoma Pharmaceuticals Inc. - notizie pubblicate 116 - letture 1.370
SONOMA PHARMACEUTICALS INC.
Sonoma Pharmaceuticals, Inc. Investor Presentation October 2023 - Form 8-K
Sonoma pharmaceuticals, inc. investor presentation october 2023 legal disclaimers investor presentation this communication is for informational purposes only. the information conta ...
SONOMA PHARMACEUTICALS INC.
Failure to Satisfy Listing Rule - Form 8-K
Item 3.01 notice of delisting or failure to satisfy a continued listing rule or standard; transfer of listing. on september 22, 2023, we received a letter from the listing qualific ...
SONOMA PHARMACEUTICALS INC.
Initial Registration Statement - Form S-1
Table of contents as filed with the securities and exchange commission on september 19, 2023. registration no. 333- united states securities and exchange commission washington, dc ...
SONOMA PHARMACEUTICALS INC.
Additional Proxy Soliciting Materials - Form DEFA14A
United states securities and exchange commission washington, dc 20549 schedule 14a proxy statement pursuant to section 14(a) of the securities exchange act of 1934 filed by the reg ...
SONOMA PHARMACEUTICALS INC.
National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced
August 15, 2023 national eczema association awards seal of acceptance to sonoma pharmaceuticals for reliefacyn advanced boulder, co / accesswire / august 15, 2023 /sonoma pharmaceu ...
SONOMA PHARMACEUTICALS INC.
Sonoma Pharmaceuticals Reports First Fiscal Quarter 2024 Financial Results
August 10, 2023 sonoma pharmaceuticals reports first fiscal quarter 2024 financial results revenue increased 6% in the first fiscal quarter compared to the same period last year, e ...
SONOMA PHARMACEUTICALS INC.
Quarterly Report for Quarter Ending June 30, 2023 (Form 10-Q)
Table of contents united states securities and exchange commission washington, dc 20549 form 10-q ☒quarterly report pursuant to section 13 or 15(d) of the securities exchange act ...
SONOMA PHARMACEUTICALS INC.
Sonoma Pharmaceuticals Announces Appointment of Hye Jin Chung, M.D. to Scientific Advisory Board
August 3, 2023 sonoma pharmaceuticals announces appointment of hye jin chung, m.d. to scientific advisory board boulder, co / accesswire / august 3, 2023 /sonoma pharmaceuticals, i ...
SONOMA PHARMACEUTICALS INC.
Initial Statement of Beneficial Ownership - Form 3
Form 3 united states securities and exchange commission washington, d.c. 20549initial statement of beneficial ownership of securities filed pursuant to section 16(a) of the securit ...
SONOMA PHARMACEUTICALS INC.
Management Change - Form 8-K
United states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of repor ...
SONOMA PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchange commission washingt ...
SONOMA PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchange commission washingt ...
SONOMA PHARMACEUTICALS INC.
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2023 Financial Results
June 22, 2023 sonoma pharmaceuticals reports fiscal year and fourth quarter 2023 financial results revenues increased 31% in q4 2023 compared to q4 2022 revenues increased 5% in fy ...
SONOMA PHARMACEUTICALS INC.
Annual report pursuant to Section 13 and 15(d)
Table of contents united states securities and exchange commission washington, d.c. 20549 form 10-k (mark one) ☒ annual report pursuant to section 13 or 15(d) of the securities e ...
SONOMA PHARMACEUTICALS INC.
Annual Report for Fiscal Year Ending March 31, 2023 (Form 10-K)
Table of contents united states securities and exchange commission washington, d.c. 20549 form 10-k (mark one) ☒ annual report pursuant to section 13 or 15(d) of the securities e ...
Per i consulenti finanziari
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti